Search Bar & Filters
Found 2 Actively Recruiting clinical trials
Actively Recruiting
Researchers are studying Medicare beneficiaries with Lumbar Spinal Stenosis LSS and Neurogenic Claudication NC to compare outcomes after two different procedures MILD Percutaneous Image-Guided Lumbar Decompression and Interspinous Process Decompression IPD. This observational study tracks patients treated since January 1, 2017, evaluating the rates of surgical and minimally invasive interventions as well as any harms related to these procedures over 24 months. The study uses Medicare claims data and does not require prior patient consent or IRB oversight. The study includes two groups of patients those who received the MILD procedure, involving partial decompression under image guidance by removing tissue and bone at the affected spinal level, and those who underwent IPD, a device-based decompression technique. Both groups are observed through Medicare data for two years after their initial procedure to assess the need for further surgeries or interventions and to monitor for any complications. Participants are followed for 24 months after their index procedure using Medicare claims data. Researchers monitor the rates of harms associated with the initial treatment and the frequency of additional surgical or minimally invasive interventions. Since this is an observational study, data collection relies on existing Medicare records without direct patient involvement, and the study will continue enrolling patients until the sponsor stops it.
Actively Recruiting
Researchers are evaluating Dabogratinib TYRA-300 in a Phase 2AB study involving participants with Low Grade Upper Tract Urothelial Carcinoma LG UTUC. This open-label, multi-center trial aims to assess the safety and effectiveness of Dabogratinib in treating this specific type of urothelial carcinoma, focusing on participants with FGFR3 positive tumors. The study is sponsored by Tyra Biosciences, Inc and includes randomized treatment groups receiving different doses of Dabogratinib. Participants receive Dabogratinib as a self-administered oral tablet daily at either 60mg or 80mg doses. The study includes two treatment cohorts and is designed to monitor the drugs impact on tumor response, including complete response rates and duration of response. The trial allows evaluation over a period of up to 36 months for response duration and up to 2 years for safety, renal preservation, and tumor resectability changes. During the trial, participants undergo assessments to measure tumor response, safety, and tolerability. Marker lesions are identified prior to randomization and monitored throughout. Researchers track outcomes including complete response rates within 6 months, maintenance of response at 12 and 24 months, and kidney function preservation. Laboratory tests, imaging, and clinical evaluations are performed regularly. The total participation time can extend up to several years to capture long-term effects and safety data.